Is $3m R&D cash rebate around May next year a fair assumption based on $6-$7m spend this calendar year?
Add that to existing cash $2-$3m allowing for cash burn current quarter and reduced cash burn moving forwards.
As a shell it looks ok at current market cap near $2m.
- Forums
- ASX - By Stock
- DLM
- Ann: Results of Phase 2 Clinical Trial
Ann: Results of Phase 2 Clinical Trial, page-83
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online